See results from the phase 1b/2 study of $EXEL third-generation TKI in combination with an immune checkpoint inhibitor in patients with metastatic #ColorectalCancer at #GI25. Read more: bit.ly/3Cn0egV.

ATTN $EXEL Investors: Q4 and Full Year 2024 earnings webcast coming soon. Details: bit.ly/42xJ2zT.

ATTN Investors: $EXEL Q4 and Full Year 2024 earnings announcement details available here: bit.ly/4jS8rL0.

Attending #GU25? Find us at Tabletop #8 to learn about our oncology pipeline and recent clinical developments.

Final 5-year results from trial of $EXEL flagship product in combination with @BMSnews immunotherapy for patients with advanced #KidneyCancer presented at #GU25. Read more: bit.ly/3CGW7fZ.

Preclinical data from four $EXEL pipeline molecules to be presented for the first time at #AACR25. Read more: bit.ly/3QKqF3P.

NEWS: We are excited to announce that the U.S. Food and Drug Administration has approved $EXEL flagship therapy for the treatment of previously treated advanced #NeuroendocrineTumors (NET). Details here: bit.ly/42rjTWb.

See our 2024 Annual Report to learn how the growth of our flagship therapy is further fueling a new generation of our medicines: bit.ly/3GfjkqT. $EXEL

Attending #AACR25? Find us at booth #3831 to learn about our recent clinical developments and oncology pipeline.

We appreciated the opportunity to support this year's AACR Foundation Scientist <-> Survivor program, which fosters relationships between scientific and advocacy community leaders. #AACR25

ATTN $EXEL Investors: Q1’25 earnings webcast coming soon. Details: bit.ly/4d7TilS.

ATTN Investors: $EXEL Q1’25 earnings announcement details available here: bit.ly/457TLSU.

Dusty finds strength through family connection, self-advocacy and learning as much as she can following her diagnosis of #NeuroendocrineTumors (NET). Watch as Dusty shares her experiences and the many sources of hope in her life.

See results from an expansion cohort of the phase 1b/2 study of our third-generation TKI in combination with immune checkpoint inhibitors in advanced #KidneyCancer at #ASCO25. Data from multiple dose-finding cohorts will also be presented: bit.ly/3YTuQPd. $EXEL

Attending #ASCO25? Find us at booth #27059 to learn about our oncology pipeline and recent clinical developments.

Just announced: Our partner Ipsen received a positive CHMP opinion in the EU for $EXEL flagship therapy for patients with previously treated advanced #NeuroendocrineTumors. Learn more: bit.ly/4nc8WBe.

Positive findings announced from a phase 3 pivotal trial of $EXEL third-generation TKI in combination with an immunotherapy in patients with metastatic #ColorectalCancer. Details available here: bit.ly/3T675jB.

ATTN $EXEL Investors: Q2 earnings webcast coming soon. Details: bit.ly/40SObki.

NEWS: Our partner Ipsen received European Commission approval of $EXEL flagship therapy for patients with previously treated advanced #NeuroendocrineTumors (NET). Learn more: bit.ly/4kZIvMX.

ATTN Investors: $EXEL Q2 earnings announcement details available here: bit.ly/4kYypf6.